Financially, UroGen has a market cap of $464mn and a cash runway of 8-9 quarters, despite facing patent challenges from Teva.

This study presents fundamental insights into overcoming resistance in hormone receptor-positive breast cancer by demonstrating that sustained CDK4/6 inhibitor treatment, either alone or in ...

Today, Feb. 1, 2025, the moon is 3 days old, in the waxing crescent phase of its lunar cycle. It is 13% illuminated. Moon phases reveal the passage of time in the night sky. Some nights when we ...

SYDNEY, Australia - Immutep Limited (NASDAQ:IMMP), a biotechnology company specializing in pharmaceutical preparations with a ...

I f the thought of your skincare routine feels more like a full-time job than a treat, you’re not alone. With the constant ...

eLife is a non-profit organisation inspired by research funders and led by scientists. Our mission is to help scientists accelerate discovery by operating a platform for research communication that ...

A common aromatic shrub that has served as traditional medicine for centuries could point the way toward innovative treatments for colorectal cancer ...

Ovarian cancer is the deadliest gynecologic malignancy globally and is increasing in incidence and mortality with currently ...

A holistic or integrative approach to hair loss considers the hair growth cycle and hair loss from a nutritional, ...

Anthro Energy's Proteus is a new class of injectable phase-change electrolytes that impart advanced features into lithium-ion ...

Acrivon Therapeutics, Inc. (ACRV – Research Report) received a Buy rating and price target from Cantor Fitzgerald analyst Li Watsek today.

Data from the Phase 3 PALOMA-3 study showed non-inferiority to intravenous administration meeting both co-primary pharmacokinetic (PK) endpoints, as well as a five-fold reduction in infusion-related ...